- Home
- PTLO vs CELC Comparison
PTLO vs CELC Comparison
Compare PTLO & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTLO
- CELC
- Stock Information
- Founded
- PTLO 1963
- CELC 2011
- Country
- PTLO United States
- CELC United States
- Employees
- PTLO N/A
- CELC N/A
- Industry
- PTLO Restaurants
- CELC Medical Specialities
- Sector
- PTLO Consumer Discretionary
- CELC Health Care
- Exchange
- PTLO Nasdaq
- CELC Nasdaq
- Market Cap
- PTLO 490.4M
- CELC 440.0M
- IPO Year
- PTLO 2021
- CELC 2017
- Fundamental
- Price
- PTLO $6.45
- CELC $55.46
- Analyst Decision
- PTLO Buy
- CELC Strong Buy
- Analyst Count
- PTLO 8
- CELC 5
- Target Price
- PTLO $12.19
- CELC $53.60
- AVG Volume (30 Days)
- PTLO 3.5M
- CELC 886.2K
- Earning Date
- PTLO 11-04-2025
- CELC 11-13-2025
- Dividend Yield
- PTLO N/A
- CELC N/A
- EPS Growth
- PTLO 17.90
- CELC N/A
- EPS
- PTLO 0.46
- CELC N/A
- Revenue
- PTLO $727,754,000.00
- CELC N/A
- Revenue This Year
- PTLO $6.74
- CELC N/A
- Revenue Next Year
- PTLO $10.15
- CELC N/A
- P/E Ratio
- PTLO $13.60
- CELC N/A
- Revenue Growth
- PTLO 3.62
- CELC N/A
- 52 Week Low
- PTLO $6.00
- CELC $7.58
- 52 Week High
- PTLO $15.78
- CELC $63.06
- Technical
- Relative Strength Index (RSI)
- PTLO 33.73
- CELC 54.87
- Support Level
- PTLO $6.02
- CELC $50.44
- Resistance Level
- PTLO $6.29
- CELC $63.06
- Average True Range (ATR)
- PTLO 0.23
- CELC 2.87
- MACD
- PTLO 0.07
- CELC -4.01
- Stochastic Oscillator
- PTLO 39.59
- CELC 87.82
About PTLO Portillo's Inc.
Portillos Inc serves the Chicago street food industry through high-energy and multichannel restaurants designed to ignite the senses and create memorable dining experiences. It owns and operates fast-casual restaurants in the United States, along with two food production commissaries in Illinois. Its menu includes hot dogs, beef and sausage sandwiches, sandwiches and ribs, salads, burgers, chicken, Barnelli's pasta, sides and soup, and desserts and shakes.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.